- Erythropoietin drugs control erythropoiesis as well as production of red blood cells.
- The erythropoietin market is driven by growing prevalence of chronic diseases like cancer, AIDA and renal diseases.
- North America is the largest market due to constantly growing cancer populace and patients suffering from renal diseases in North America.
Erythropoietin drugs are also known as hematopoietin, which controls erythropoiesis as well as production of red blood cells. They are used to treat various diseases like cancer, chronic renal diseases, AIDS, anemia and other ailments.
The erythropoietin market is driven by growing prevalence of chronic diseases like cancer, AIDA and renal diseases. Introduction of new drugs and different government initiatives for research are also boosting the growth of erythropoietin drugs market. However, the high cost of treatment, as well as side effects of the treatment, are limiting market growth.
The global erythropoietin drugs market was valued $7.6 Bn in 2017 and is expected to reach $17.8 Bn by 2026, at a CAGR of 11.22 % during a forecast period.
Biosimilar is the fastest growing segment in the erythropoietin drugs market, especially in developing countries, due to low-cost therapeutics and enhanced efficacy. Biosimilar is easy to adapt & improve, cost-effective, and requires less time for approval as compared to biologics and are expected to gain popularity in the near future for the treatment of anemic conditions.
In cancer patients, almost 77% suffer from anemia, which is often overlooked as tiredness. Anemia is generally associated with cancer, owing to chemotherapy treatment, blood loss, marrow tumor, nutritional deficiency, but is mostly caused due to cytokine production.
Retail pharmacies lead the distribution channel segment with a huge share. Retail pharmacies provide advice about health issues, symptoms & medications in response to customer inquiries. They also recruit, train & manage staff, treat prescriptions & dispense medication. Retail pharmacies additionally are preparing publicity materials & displays, managing budgets, and keeping statistical & financial records.
I Give You Masterclass Poker Course by Nick Petrangelo
Buy Research Report: Radiology Information Systems Market to Witness A Steep CAGR Of 8.3%
Buy Research Report: Mobile Water Treatment Systems Market Set to Grow US$ 1,952.0 Mn during 2020-2030
Buy Research Report: Electric Trolling Motors Market to Expand at a CAGR of 3.2% During 2020-2030
Buy Research Report: Global Solar Cells and Modules Market Strategic Assessment and Forecast by 2026
North America is the largest market, followed by Europe during the forecast period due to constantly growing cancer populace and patients suffering from renal diseases in North America. Technological advance and government initiatives for research are also leading the largest market in this region. Growing purchasing power, rapid growth in infrastructure, rising medical tourism and expansion in available treatments is increasing the growth of the Asia Pacific region in the erythropoietin drugs market during the forecast period.
Key players operating in the global erythropoietin drugs market are Amgen, Hoffmann-LA Roche, Johnson & Johnson, and Kyowa Hakko Kirin.
The report covers a comprehensive study of major market drivers, restrains, opportunities, challenges, PESTEL, Porters, SWOT, and technological forecasting in the market.
Global Erythropoietin Drugs Market, by Drug Class: Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa. Global Erythropoietin Drugs Market, by Drug Type: Biologics and Biosimilar. Global Erythropoietin Drugs Market, by Drug Application: Cancer, Renal Disease, Hematology, Neurology, and Surgery & Wound Healing. Global Erythropoietin Drugs Market, by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy.